Vivus Fattens Wallet with $45.8 million offering to support obesity drug
This article was originally published in Scrip
Executive Summary
Still trying to get its experimental weight loss drug Qnexa (phentermine/topiramate) approved in the US – and having to sink some more cash into that endeavour – Vivus raised $45.8 million from selling 6.9 million shares of its common stock at $6.65 per share to a select group of institutional investors – an offering that was consummated on 24 August.